Extracorporeal Artificial Lungs: Co-Creating Future Technology - A Qualitative Analysis.
artificial lung
chronic obstructive pulmonary disease
patient feedback
pulmonary hypertension
Journal
Medical devices (Auckland, N.Z.)
ISSN: 1179-1470
Titre abrégé: Med Devices (Auckl)
Pays: New Zealand
ID NLM: 101566041
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
03
2023
accepted:
10
07
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Terminal lung diseases such as chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH) in progression cause a large reduction in quality of life and may lead to bilateral lung transplantation (bLTx). An artificial portable lung could provide a bridge to lung transplantation, allowing patients to remain at home and mobile for longer. To advance the development of such an artificial lung, patient feedback is essential. The aim of this study is to analyze patient acceptance about an extracorporeal artificial lung and to implement these findings into the development. In collaboration with a medical device developer, we presented a portable dummy oxygenator to patients with advanced lung disease, as potential end users. Data collection in Germany and France was based on two different methods: an online questionnaire and face-to-face interviews (F2F). A total of 604 participants answered the online questionnaire and 17 participants were included in the F2F interviews. The majority of participants (COPD n=140, PH n=17) were able to walk more than 1 km with a mean suffering pressure of 2.87 and 3, respectively. Six of the 17 F2F participants who could walk <1 km were interested in an assistive device. The statistical value of Fisher's exact test for suffering pressure and desire for a portable oxygenator was 0.45. In patients with advanced lung disease, there is no statistically significant association between subjectively increased suffering pressure and desire for a portable oxygenator, so market introduction may be difficult. Potential end users should be implemented early in device development. Data collection via an online questionnaire combined with personal interviews has proven to be a successful approach here.
Sections du résumé
Background
UNASSIGNED
Terminal lung diseases such as chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH) in progression cause a large reduction in quality of life and may lead to bilateral lung transplantation (bLTx). An artificial portable lung could provide a bridge to lung transplantation, allowing patients to remain at home and mobile for longer. To advance the development of such an artificial lung, patient feedback is essential. The aim of this study is to analyze patient acceptance about an extracorporeal artificial lung and to implement these findings into the development.
Methods
UNASSIGNED
In collaboration with a medical device developer, we presented a portable dummy oxygenator to patients with advanced lung disease, as potential end users. Data collection in Germany and France was based on two different methods: an online questionnaire and face-to-face interviews (F2F).
Results
UNASSIGNED
A total of 604 participants answered the online questionnaire and 17 participants were included in the F2F interviews. The majority of participants (COPD n=140, PH n=17) were able to walk more than 1 km with a mean suffering pressure of 2.87 and 3, respectively. Six of the 17 F2F participants who could walk <1 km were interested in an assistive device. The statistical value of Fisher's exact test for suffering pressure and desire for a portable oxygenator was 0.45.
Conclusion
UNASSIGNED
In patients with advanced lung disease, there is no statistically significant association between subjectively increased suffering pressure and desire for a portable oxygenator, so market introduction may be difficult. Potential end users should be implemented early in device development. Data collection via an online questionnaire combined with personal interviews has proven to be a successful approach here.
Identifiants
pubmed: 37533746
doi: 10.2147/MDER.S415258
pii: 415258
pmc: PMC10392817
doi:
Types de publication
Journal Article
Langues
eng
Pagination
201-210Informations de copyright
© 2023 Dormann et al.
Déclaration de conflit d'intérêts
Dr Sebastian Wendt reports he is a full time employee at Abiomed Europe GmbH since July 2020 which was for him after the relevant time for this project. None of the authors have any relevant conflict of interest to declare.
Références
Dtsch Arztebl Int. 2017 Feb 3;114(5):73-84
pubmed: 28241922
Eur Respir Rev. 2023 Mar 22;32(167):
pubmed: 36948499
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Pulm Circ. 2011 Apr-Jun;1(2):182-91
pubmed: 22034605
J Thorac Cardiovasc Surg. 2022 Oct;164(4):1222-1233.e11
pubmed: 35016781
J Am Coll Cardiol. 2018 Oct 2;72(14):1640-1652
pubmed: 30261966
ASAIO J. 2009 May-Jun;55(3):304-6
pubmed: 19282751
Int J Chron Obstruct Pulmon Dis. 2019 Jul 05;14:1423-1439
pubmed: 31308648
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
Clin Chest Med. 2014 Mar;35(1):1-6
pubmed: 24507832